Capricor Therapeutics Shares Insights at Major Conferences

Capricor Therapeutics to Showcase Innovations at Leading Conferences

SAN DIEGO, a notable biotechnology company known for its commitment to transformative therapies, is set to present at significant investor and scientific conferences in the coming weeks. Capricor Therapeutics (NASDAQ: CAPR) specializes in developing cell and exosome-based therapeutics targeting rare diseases, and the upcoming events promise to shed light on its advances.

Upcoming Conference Events

Capricor will participate in several key conferences where it will present insights regarding its groundbreaking advancements and future strategies. Details of the presentations are as follows:

H.C. Wainwright Annual Global Investment Conference

Scheduled for September 9, 2024, at 2:00 p.m. ET, this conference will feature a company presentation and one-on-one meetings, providing a platform for Capricor to engage with investors and stakeholders alike.

Annual Exosome-Based Therapeutic Summit

Taking place from September 17 to 19, 2024, in Boston, this summit is key for industry leaders. Capricor's participation includes a company presentation and an industry panel focused on exosome therapies.

2024 Cantor Fitzgerald’s Global Healthcare Conference

This conference offers another opportunity for Capricor to present its progress, scheduled for September 18, 2024, at 8:35 a.m. ET, featuring a fireside chat and one-on-one meetings.

Key Updates on Deramiocel

During these conferences, Capricor's management will highlight updates regarding deramiocel, the company’s leading product candidate intended for the treatment of Duchenne muscular dystrophy (DMD). Deramiocel (CAP-1002) is progressing through critical phases of clinical development, demonstrating promising results in treating this serious condition.

About Capricor Therapeutics

Capricor Therapeutics (NASDAQ: CAPR) is dedicated to advancing cell and exosome-based therapeutics aimed at revolutionizing treatment for rare diseases. The lead candidate, deramiocel, is a cardiac-derived cell therapy that has shown immunomodulatory, antifibrotic, and regenerative properties in extensive preclinical and clinical settings.

Currently, deramiocel is in Phase 3 clinical trials for DMD, a severe genetic disorder characterized by progressive muscle degeneration. The company is also exploring exosome technology through its proprietary StealthX™ platform to facilitate targeted delivery of therapies for various diseases.

Capricor remains steadfast in its mission to innovate and advance treatments for patients with unmet medical needs, advocating for their health and well-being. More information about Capricor's innovative efforts can be found on their official website, capricor.com.

Frequently Asked Questions

What is the focus of Capricor Therapeutics?

Capricor Therapeutics is focused on developing transformative therapies for rare diseases, particularly using cell and exosome-based therapeutics.

When is Capricor presenting at the H.C. Wainwright Annual Global Investment Conference?

The presentation is scheduled for September 9, 2024, at 2:00 p.m. ET.

What is deramiocel?

Deramiocel (CAP-1002) is Capricor's lead product candidate, aimed at treating Duchenne muscular dystrophy, showing promise in clinical development.

Which technologies is Capricor developing?

Capricor is developing its proprietary StealthX™ platform, utilizing exosome technology for targeted therapeutic delivery.

How can I learn more about Capricor's clinical trials?

To get detailed information about clinical trials and developments, visit Capricor's official website.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.